Literature DB >> 24615976

Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach.

Harel Dahari1, Scott J Cotler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24615976      PMCID： PMC3977009          DOI： 10.1002/hep.26772

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  4 in total

1.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

2.  Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Authors:  Jeremie Guedj; Alan S Perelson
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

3.  Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.

Authors:  Harel Dahari; Arthur Lo; Ruy M Ribeiro; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-03-14       Impact factor: 2.691

4.  Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

Authors:  Brian L Pearlman; Carole Ehleben
Journal:  Hepatology       Date:  2013-11-18       Impact factor: 17.425
  4 in total
  3 in total

1.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Authors:  Harel Dahari; Laetitia Canini; Frederik Graw; Susan L Uprichard; Evaldo S A Araújo; Guillaume Penaranda; Emilie Coquet; Laurent Chiche; Aurelie Riso; Christophe Renou; Marc Bourliere; Scott J Cotler; Philippe Halfon
Journal:  J Hepatol       Date:  2016-02-22       Impact factor: 25.083

2.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

3.  Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Alan S Perelson
Journal:  Antivir Ther       Date:  2014-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.